Compare VRTS & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTS | BBOT |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1992 | N/A |
| Metric | VRTS | BBOT |
|---|---|---|
| Price | $174.49 | $13.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $176.40 | $23.80 |
| AVG Volume (30 Days) | 76.8K | ★ 259.9K |
| Earning Date | 01-30-2026 | 02-26-2026 |
| Dividend Yield | ★ 5.60% | N/A |
| EPS Growth | ★ 18.44 | N/A |
| EPS | ★ 19.47 | N/A |
| Revenue | ★ $878,336,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $142.18 | $8.50 |
| 52 Week High | $215.90 | $14.87 |
| Indicator | VRTS | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 62.86 | N/A |
| Support Level | $163.88 | N/A |
| Resistance Level | $171.41 | N/A |
| Average True Range (ATR) | 4.31 | 0.00 |
| MACD | 0.95 | 0.00 |
| Stochastic Oscillator | 90.03 | 0.00 |
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.